KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Income towards Parent Company (2016 - 2026)

Jazz Pharmaceuticals has reported Income towards Parent Company over the past 15 years, most recently at $203.5 million for Q4 2025.

  • For Q4 2025, Income towards Parent Company rose 6.49% year-over-year to $203.5 million; the TTM value through Dec 2025 reached -$263.4 million, down 146.89%, while the annual FY2025 figure was -$355.4 million, 163.27% down from the prior year.
  • Income towards Parent Company for Q4 2025 was $203.5 million at Jazz Pharmaceuticals, down from $251.4 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $251.4 million in Q3 2025 and troughed at -$718.4 million in Q2 2025.
  • A 5-year average of $9.1 million and a median of $70.4 million in 2023 define the central range for Income towards Parent Company.
  • Biggest five-year swings in Income towards Parent Company: crashed 641.94% in 2022 and later skyrocketed 1116.53% in 2023.
  • Year by year, Income towards Parent Company stood at -$32.3 million in 2021, then crashed by 641.94% to -$240.0 million in 2022, then surged by 139.43% to $94.6 million in 2023, then surged by 101.96% to $191.1 million in 2024, then rose by 6.49% to $203.5 million in 2025.
  • Business Quant data shows Income towards Parent Company for JAZZ at $203.5 million in Q4 2025, $251.4 million in Q3 2025, and -$718.4 million in Q2 2025.